Q1 Earnings Forecast for APLS Issued By William Blair

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Stock analysts at William Blair issued their Q1 2025 earnings estimates for Apellis Pharmaceuticals in a report issued on Monday, October 28th. William Blair analyst L. Hanbury-Brown anticipates that the company will earn ($0.09) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.37) per share. William Blair also issued estimates for Apellis Pharmaceuticals’ Q2 2025 earnings at $0.06 EPS and Q3 2025 earnings at $0.13 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The business had revenue of $199.70 million during the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The company’s revenue was up 110.2% on a year-over-year basis. During the same period in the prior year, the business posted ($1.02) earnings per share.

A number of other equities analysts have also weighed in on APLS. Robert W. Baird dropped their target price on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating for the company in a research report on Monday, September 23rd. Mizuho dropped their target price on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research report on Thursday, October 24th. Jefferies Financial Group restated a “buy” rating and set a $80.00 target price on shares of Apellis Pharmaceuticals in a research report on Wednesday, July 31st. Royal Bank of Canada initiated coverage on shares of Apellis Pharmaceuticals in a research report on Friday, October 25th. They set a “sector perform” rating and a $25.00 target price for the company. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a research report on Friday, September 13th. Five research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Apellis Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $65.41.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ:APLS opened at $27.71 on Thursday. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.18 and a current ratio of 5.08. The firm has a fifty day moving average price of $32.76 and a 200 day moving average price of $38.01. Apellis Pharmaceuticals has a fifty-two week low of $26.28 and a fifty-two week high of $73.80. The firm has a market cap of $3.36 billion, a price-to-earnings ratio of -8.01 and a beta of 0.87.

Institutional Trading of Apellis Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Apellis Pharmaceuticals in the first quarter worth about $89,000. nVerses Capital LLC increased its position in shares of Apellis Pharmaceuticals by 300.0% during the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after acquiring an additional 2,100 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Apellis Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after acquiring an additional 781 shares in the last quarter. CWM LLC boosted its holdings in shares of Apellis Pharmaceuticals by 299.9% in the second quarter. CWM LLC now owns 4,151 shares of the company’s stock valued at $159,000 after purchasing an additional 3,113 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in Apellis Pharmaceuticals by 1,300.8% in the first quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company’s stock worth $211,000 after purchasing an additional 3,330 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insider Buying and Selling at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).